Clinical trialNCT06456463RecruitingPhase 2Interventional

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

SponsorStemline Therapeutics, Inc.Enrollment83Acute Myeloid Leukemia

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

32 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Concord Repatriation General Hospital
Concord, New South Wales, Australia
Robin Gasiorowski, MBBS
Recruiting
Townsville Hospital
Douglas, Queensland, Australia
Rachael Boles, MD
Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Devendra Hiwase, MBBS
Recruiting
Box Hill Hospital
Box Hill, Victoria, Australia
Stephen Ting, MBBS
Recruiting
Monash Medical Centre
Clayton, Victoria, Australia
Ashvind Prabahran, MD
Recruiting
St. Vincents Hospital
Fitzroy, Victoria, Australia
Shuh Ying Tan, MBBS
Recruiting
Austin Hospital
Heidelberg, Victoria, Australia
Chun Yew Fong, MBBS, PhD
Recruiting
Royal Perth Hospital
Perth, Western Australia, Australia
Hun Chuah, MBBS, PhD
Recruiting

United States

University of California, Los Angeles
Los Angeles, California, United States
Gary Schiller, MD
Recruiting
Stanford Health Care
Stanford, California, United States
Gabriel Mannis, MD
Recruiting
University of Miami
Miami, Florida, United States
Namrata Chandhok, MD
Recruiting
Adventhealth Cancer Institute
Orlando, Florida, United States
Shahram Mori, MD, PhD
Recruiting
University of Chicago
Chicago, Illinois, United States
Anand Patel, MD
Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Malgorzata McMasters, MD
Recruiting
Dana Farber Cancer Institute (dfci)
Boston, Massachusetts, United States
Andrew A Lane, MD, PhD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Amir Fathi, MD
Recruiting
Henry Ford Health System Brigitte Harris Cancer Pavillion
Detroit, Michigan, United States
Christopher A Willner II, DO
Recruiting
Washington University - Siteman Cancer Center
St Louis, Missouri, United States
Geoffrey L Uy, MD
Recruiting
John Theurer Cancer Center - Hackensack Meridian Health
Hackensack, New Jersey, United States
James K McCloskey, MD
Recruiting
Rutgers Cancer Institute
New Brunswick, New Jersey, United States
Neil D Palmisiano, MD, MS
Recruiting
Roswell Park Cancer Institute
Buffalo, New York, United States
Eunice S Wang, MD
Recruiting
North Shore University Hospital
Manhasset, New York, United States
David Chitty, MD
Recruiting
Columbia University Irving Medical Center
New York, New York, United States
Sunil Iyer, MD
Recruiting
Nyu Langone Health
New York, New York, United States
Jun H Choi, MD
Recruiting
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, United States
Abhishek Chilkulwar, MD
Recruiting
Novant Health Derrick L Davis Cancer Center
Winston-Salem, North Carolina, United States
Abhishek Chilkulwar, MD
Recruiting
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Akriti Jain, MD
Recruiting
Sydney Kimmel (thomas Jefferson University)
Philadelphia, Pennsylvania, United States
Gina Keiffer, MD
Recruiting
Sarah Cannon, the Cancer Institute of Hca Healthcare
Nashville, Tennessee, United States
Stephen A Strickland, MD
Recruiting
Tennessee Oncology
Nashville, Tennessee, United States
Jonathan Abbas, MD
Recruiting
Baylor Scott & White Health
Dallas, Texas, United States
Bradley W Christensen, MD
Recruiting
University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Naval G Daver, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azacitidine →Tagraxofusp →Venetoclax →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Jan 2025
Primary completion: 9 Feb 2028
Completion: 11 Feb 2030
Last update posted: 9 Mar 2026
Registered enrollment: 83
Registry id: NCT06456463

Cross-registrations

EU-CTR / CTIS (EudraCT)2024-514660-48

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.